These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 25731133)
21. Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention. Bohula EA; Morrow DA; Giugliano RP; Blazing MA; He P; Park JG; Murphy SA; White JA; Kesaniemi YA; Pedersen TR; Brady AJ; Mitchel Y; Cannon CP; Braunwald E J Am Coll Cardiol; 2017 Feb; 69(8):911-921. PubMed ID: 28231942 [TBL] [Abstract][Full Text] [Related]
22. Increasing doses of simvastatin versus combined ezetimibe/simvastatin: effect on circulating endothelial progenitor cells. Pesaro AE; Serrano CV; Katz M; Marti L; Fernandes JL; Parra PR; Campos AH J Cardiovasc Pharmacol Ther; 2013 Sep; 18(5):447-52. PubMed ID: 23739650 [TBL] [Abstract][Full Text] [Related]
23. A case study of single-pill combination therapy: the ezetimibe/simvastatin combination for treatment of hyperlipidemia. Huang X; Chen DY ChemMedChem; 2012 Nov; 7(11):1882-94. PubMed ID: 22907901 [TBL] [Abstract][Full Text] [Related]
24. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Pearson T; Ballantyne C; Sisk C; Shah A; Veltri E; Maccubbin D Am J Cardiol; 2007 Jun; 99(12):1706-1713. PubMed ID: 17560879 [TBL] [Abstract][Full Text] [Related]
30. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome. Robinson JG; Ballantyne CM; Hsueh WA; Rosen JB; Lin J; Shah AK; Tomassini JE; Lowe RS; Tershakovec AM J Clin Lipidol; 2013; 7(4):292-303. PubMed ID: 23890516 [TBL] [Abstract][Full Text] [Related]
31. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Pearson TA; Denke MA; McBride PE; Battisti WP; Brady WE; Palmisano J Mayo Clin Proc; 2005 May; 80(5):587-95. PubMed ID: 15887425 [TBL] [Abstract][Full Text] [Related]
33. The ezetimibe controversy: implications for clinical practice. Khanderia U; Regal RE; Rubenfire M; Boyden T Ther Adv Cardiovasc Dis; 2011 Aug; 5(4):199-208. PubMed ID: 21636623 [TBL] [Abstract][Full Text] [Related]
34. Lipid-lowering therapy does not affect the postprandial drop in high density lipoprotein-cholesterol (HDL-c) plasma levels in obese men with metabolic syndrome: a randomized double blind crossover trial. Hajer GR; Dallinga-Thie GM; van Vark-van der Zee LC; Olijhoek JK; Visseren FL Clin Endocrinol (Oxf); 2008 Dec; 69(6):870-7. PubMed ID: 18394022 [TBL] [Abstract][Full Text] [Related]
35. The effect of simvastatin-ezetimibe combination therapy on adipose tissue hormones and systemic inflammation in patients with isolated hypercholesterolemia. Krysiak R; Zmuda W; Okopien B Cardiovasc Ther; 2014 Apr; 32(2):40-6. PubMed ID: 24354929 [TBL] [Abstract][Full Text] [Related]
36. Controversies surround heart drug study: questions about Vytorin and trial sponsors' conduct. Mitka M JAMA; 2008 Feb; 299(8):885-7. PubMed ID: 18314425 [No Abstract] [Full Text] [Related]